Targeting the protein hepsin may be a viable option for treating diabetes.
Launch of the phase 3 Lp(a) HORIZON trial of a novel antisense oligonucleotide therapy for reducing elevated Lp(a) may signal the first real therapeutic progress on a final frontier of lipid management.
The largest-ever cohort study of familial chlyomicronemia syndrome finds the lipid disorder to be less rare than thought and triglycerides > 750 mg/dL to dramatically raise cardiac risk regardless of the cause.
The ACCELERATE trial found no effect on cardiac events with evacetrapib despite large HDL gains and solid LDL declines. A substudy presented at ESC 2017 now shows the drug fared no better when analysis was limited to diabetic patients.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
This free Thursday dinner symposium at ACC.17 can help attendees make the most of the many advancements discussed at the larger meeting. The course directors explain why you shouldn’t miss it.
Three-quarters of a sample of obese kids had at least one obesity-related comorbidity, and nearly half had two or more comorbidities. Check out these and other insights from the clinic’s early research initiatives.